Prevention of infection in Liver Failure Patients.
Not Applicable
Completed
- Conditions
- Health Condition 1: K729- Hepatic failure, unspecified
- Registration Number
- CTRI/2019/10/021548
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 143
Inclusion Criteria
ACLF patients aged between 18-75 years, either admitted or attending the out-patient department will be recruited for the study.
Exclusion Criteria
1. Patients with sepsis â?? fever, positive blood, and urine cultures, procalcitonin >2, Allergy to fluoroquinolones.
2.Patients in the intensive care unit
3.Renal failure (S. Creatinine >2.5mg%)
4.Pregnancy
5.Patients with a history of Spontaneous bacterial peritonitis
6.Patients with shock requiring vasopressor support
7.Patients with malignancy
8.Recent Gastrointestinal bleeding ( <7 days)
9.Patients with a history of Hepatic encephalopathy and /or on Rifaximin therapy
10.Patients who received fluoroquinolones in last one month
11.Patients on intravenous antibiotics
12.Refusal to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of sepsisTimepoint: at day 30
- Secondary Outcome Measures
Name Time Method Effect of norfloxacin on Endotoxin levelsTimepoint: on day 7, 30;To study the safety and tolerability of the Norfloxacin.Timepoint: at day 30;Transplant-free survivalTimepoint: at day 30, 90.